16 September 2026 editorial review · Trial
iPancreas context-aware fully closed-loop AID: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Primary-agent trial review — 16 September 2026
Assessment: Removed unrelated amylin treatment link and flagged passed registry estimate; no assumed completion.
Registry: NCT06676657; RECRUITING; updated 2025-04-11; enrollment 10 (ESTIMATED); results not posted.
Endpoint comparison: Percent of time with sensor glucose less than 70 mg/dl (entire 4 week study); Percent of time with sensor glucose less than 54 mg/dl (entire 4 week study); Percent of time the pattern evaluation windows occurred (entire 4 week study); Percent of time with sensor glucose greater than 250 mg/dl (entire 4 week study).
Sources for this record: NCT06676657: iPancreas context-aware fully closed-loop AID (registry).
Limits: Source access and review depth vary. Registry fields establish the registered study, not clinical benefit, product approval or current local access. Cited-source reachability alone was not treated as verification of its claims.